Through a series of experiments, Zhang et al. (2017) demonstrated that the expression of lncRNA CDKN2B-AS1 is remarkably high in both cervical cancer tissues and cell lines, and the CDKN2B-AS1 may take an essential part in the progression of cervical cancer, implying that CDKN2B-AS1 may work as a new cervical cancer therapeutic target and prognostic biomarker. This evidence concerns the gene CDKN2B and cervical carcinoma.